About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

Astellas Pharma Inc.(4503) Financial Results

4503
TSE Prime
Astellas Pharma Inc.
1,515.5
JPY
-27.0
(-1.75%)
Dec 23, 3:11 pm JST
9.67
USD
Dec 23, 1:00 am EST
Result
PTS
outside of trading hours
1,515.2
Dec 23, 3:11 pm JST
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2021 1,249,528 136,051 145,324 120,589 64.9 42 Apr 27, 2021 IFRS
Mar, 2022 1,296,163 155,686 156,886 124,086 67.1 50 Apr 27, 2022 IFRS
Mar, 2023 1,518,619 133,029 132,361 98,714 54.2 60 Apr 27, 2023 IFRS
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 Guidance 1,800,000 80,000 70,000 50,000 27.9 74 Oct 30, 2024 IFRS
YoY +12.2% +213.5% +180.3% +193.3% +193.7%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 1,603,672 275,904 284,193 222,265 115.1
Fiscal Year Mar, 2024 Mar, 2008 Mar, 2008 Mar, 2019 Mar, 2019
Second Half
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2021 644,497 65,517 67,801 52,477 28.4 25 Apr 27, 2022 IFRS
Oct - Mar, 2022 756,434 13,138 11,881 2,280 1.3 30 Apr 27, 2023 IFRS
Oct - Mar, 2023 836,534 -29,638 -31,349 -18,765 -10.5 35 Apr 25, 2024 IFRS
Oct - Mar, 2024 Guidance 864,379 -13,710 -19,042 -23,511 -13.1 37 Oct 30, 2024 IFRS
YoY +3.3% +53.7% +39.3% -25.3% -25.4%
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Mar, 2022 155,686 195,031 257,444 -62,413 -216,298 315,986 13.55 IFRS
Mar, 2023 133,029 243,267 327,767 -84,500 -195,623 376,840 15.34 IFRS
Mar, 2024 25,518 -673,327 172,475 -845,802 614,060 335,687 9.40 IFRS
Actual Performance and Financial Trends
Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 762,185 119,891 120,480 96,434 52.9 91.0 Oct 31, 2022 IFRS
Apr - Sep, 2023 767,138 55,156 56,318 35,810 20.0 225.6 Nov 1, 2023 IFRS
Apr - Sep, 2024 935,621 93,710 89,042 73,511 41.1 127.2 Oct 30, 2024 IFRS
YoY +22.0% +69.9% +58.1% +105.3% +105.6%
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2022 402,180 61,388 59,758 48,405 26.6 15.3 Feb 6, 2023 IFRS
Jan - Mar, 2023 354,254 -48,250 -47,877 -46,125 -25.3 -13.6 Apr 27, 2023 IFRS
Apr - Jun, 2023 374,990 45,794 46,850 33,129 18.5 12.2 Aug 1, 2023 IFRS
Jul - Sep, 2023 392,148 9,362 9,468 2,681 1.5 2.4 Nov 1, 2023 IFRS
Oct - Dec, 2023 421,932 18,963 17,312 14,513 8.1 4.5 Feb 5, 2024 IFRS
Jan - Mar, 2024 414,602 -48,601 -48,661 -33,278 -18.6 -11.7 Apr 25, 2024 IFRS
Apr - Jun, 2024 473,124 50,657 50,495 37,603 21.0 10.7 Aug 1, 2024 IFRS
Jul - Sep, 2024 462,497 43,053 38,547 35,908 20.1 9.3 Oct 30, 2024 IFRS
YoY +17.9% +359.9% +307.1% +1,239.4% +1,237.3%
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 473,124 97,253 109,053 87,668 45.1
Fiscal Year Jun, 2024 Dec, 2007 Dec, 2007 Dec, 2018 Dec, 2018
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Mar, 2022 799.26 62.6 2,332,395 1,460,308 944,261 Apr 27, 2022 IFRS
Mar, 2023 839.26 61.4 2,456,518 1,507,954 908,158 0.08 Apr 27, 2023 IFRS
Mar, 2024 890.07 44.7 3,569,603 1,595,988 809,400 0.58 Apr 25, 2024 IFRS
Apr - Sep, 2024 44.2 3,462,237 1,529,842 817,614 0.61 Oct 30, 2024 IFRS